Econazole

Summary

Econazole (CHEMBL808) is an approved small molecule (ATC D01AC03) targeting CYP8B1, TRPM2, and TRPV5; indicated across 1 condition including tinea pedis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC03 (+1 more)
• Targets: 3 (CYP8B1, TRPM2, TRPV5)
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 381.7 Da · C18H15Cl3N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL808
Name	Econazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3198
ChEBI	CHEBI:82873
ATC	D01AC03, G01AF05
Molecular formula	C18H15Cl3N2O
Molecular weight	381.7
InChIKey	LEZWWPYKPKIXLL-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl

IUPAC name: 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole

ChEBI definition: A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.

Also known as: Econazol, Econazole, NSC-187789, econazole, SID104171384, SID448079, ECONAZOLE, ECONAZOLE NITRATE

Parent form; salt/anhydrous children: CHEMBL1201049

Patent coverage: 6,935 distinct patent families (24,813 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 24,706 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CYP8B1	CYP8B1	Inhibition	6.1	0%	Q9UNU6
TRPM2	TRPM2	Antagonist		0.4%	O94759
TRPV5	TRPV5			0%	Q9NQA5

Broader ChEMBL bioactivity targets: 73 (assay-derived). Sample: Indoleamine 2,3-dioxygenase 1, Transient receptor potential cation channel subfamily M member 8, Transient receptor potential cation channel subfamily M member 2, Transient receptor potential cation channel subfamily V member 6, Mycocyclosin synthase, Muscarinic acetylcholine receptor M4, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Thromboxane-A synthase, Tyrosine-protein kinase Fyn.

Bioactivity

ChEMBL activities: 82 potent at pChembl ≥ 5 of 121 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TBXAS1	7.54	IC50	29	nM	CHEMBL_ACT_7654140
CYP2C19	7.4	IC50	40	nM	CHEMBL_ACT_7651958
CYP51A1	7.3	IC50	50	nM	CHEMBL_ACT_2122888
CYP3A4	7.3	IC50	50	nM	CHEMBL_ACT_7651966
P9WPP7	7.14	Kd	73	nM	CHEMBL_ACT_16585274
P9WPP9	6.7	Kd	200	nM	CHEMBL_ACT_5230880
CYP2C9	6.7	IC50	200	nM	CHEMBL_ACT_7651960
SLC6A4	6.65	Ki	225	nM	CHEMBL_ACT_7654127
CHRM4	6.53	Ki	296	nM	CHEMBL_ACT_7652037
CYP1A2	6.52	IC50	300	nM	CHEMBL_ACT_7651954
CYP8B1	6.51	IC50	310	nM	CHEMBL_ACT_19326115
CYP17A1	6.49	Ki	325	nM	CHEMBL_ACT_1030488
CHRM3	6.42	Ki	379	nM	CHEMBL_ACT_7652035
CYP2D6	6.4	IC50	400	nM	CHEMBL_ACT_7651962
TRPM8	6.38	IC50	420	nM	CHEMBL_ACT_25073075
CYP3A4	6.37	IC50	430	nM	CHEMBL_ACT_19453501
CYP3A4	6.37	IC50	430.5	nM	CHEMBL_ACT_2686205
SLC6A4	6.37	IC50	423	nM	CHEMBL_ACT_7654126
OPRD1	6.29	Ki	508	nM	CHEMBL_ACT_7652051
CHRM1	6.2	Ki	636	nM	CHEMBL_ACT_7652031
SLC6A3	6.18	Ki	663	nM	CHEMBL_ACT_7651977
SLC6A3	6.08	IC50	835	nM	CHEMBL_ACT_7651976
IDO1	5.96	IC50	1100	nM	CHEMBL_ACT_18571631
CHRM2	5.94	Ki	1158	nM	CHEMBL_ACT_7652033
HTR2A	5.94	Ki	1152	nM	CHEMBL_ACT_7654115
OPRD1	5.84	IC50	1442	nM	CHEMBL_ACT_7652050
HRH2	5.8	IC50	1592	nM	CHEMBL_ACT_7652004
HRH2	5.8	Ki	1565	nM	CHEMBL_ACT_7652005
ADRA2A	5.79	Ki	1622	nM	CHEMBL_ACT_7649897
DRD3	5.79	Ki	1615	nM	CHEMBL_ACT_7651973

Target pathways

Aggregated over 3 target gene(s): CYP8B1, TRPM2, TRPV5.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	2	TRPM2, TRPV5
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol	1	CYP8B1
Synthesis of bile acids and bile salts via 24-hydroxycholesterol	1	CYP8B1
Synthesis of bile acids and bile salts via 27-hydroxycholesterol	1	CYP8B1
Eicosanoids	1	CYP8B1
Sterols are 12-hydroxylated by CYP8B1	1	CYP8B1
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	1	CYP8B1
Neutrophil degranulation	1	TRPM2

Dominant GO biological processes

GO term	Targets
calcium ion transport	2
protein homotetramerization	2
calcium ion transmembrane transport	2
calcium ion transmembrane import into cytosol	2
calcium ion import across plasma membrane	2
monoatomic ion transport	2
monoatomic ion transmembrane transport	2
transmembrane transport	2
steroid biosynthetic process	1
bile acid biosynthetic process	1
sterol metabolic process	1
response to nutrient levels	1
positive regulation of intestinal cholesterol absorption	1
response to cholesterol	1
lipid metabolic process	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tinea pedis	3	MONDO:0005984	EFO:0007512

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01696799	PHASE2	COMPLETED	Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years
NCT02713893	PHASE1	COMPLETED	Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

12 molecules share ≥1 primary target. Top 12 by shared-target count:

Molecule	Source	Status	Shared targets
CLOTRIMAZOLE	ChEMBL + PubChem	Phase 4 (approved)	CYP8B1, TRPM2
MICONAZOLE	ChEMBL + PubChem	Phase 4 (approved)	CYP8B1, TRPM2
ADENOSINE	ChEMBL + PubChem	Phase 4 (approved)	TRPM2
COPPER	ChEMBL	Phase 4 (approved)	TRPM2
ITRACONAZOLE	ChEMBL	Phase 4 (approved)	CYP8B1
KETOCONAZOLE	ChEMBL	Phase 4 (approved)	CYP8B1
POSACONAZOLE	ChEMBL	Phase 4 (approved)	CYP8B1
TRANYLCYPROMINE	ChEMBL	Phase 4 (approved)	CYP8B1
FLUFENAMIC ACID	ChEMBL	Phase 2	TRPM2
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPV5
Mefenamic Acid	PubChem	Approved	TRPM2
Nadide	PubChem	Approved	TRPM2